Fulltext

Asia-Pacific Real-World Evolocumab Use, LDL-C Reduction, Physician Goals, and Patient Perceptions: HALES Observational Study

Tse HF 1 , Chang HY 2 , Colquhoun D 3 , Kim JS 4 , Poh KK 5 , Kostner K 6 Show all authors , Hutayanon P 7 , Cho M 8 , Lange J 9 , Kodiappan K 10 , Leekha S 9

Affiliations 

  • 1 Cardiology Division, Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, 410, Professorial Block, 102 Pok Fu Lam Road, Hong Kong, Hong Kong. [email protected]
  • 2 Division of Cardiology, Heart Centre, School of Medicine, Cheng Hsin General Hospital, National Yang-Ming Chiao Tung University, Taipei, Taiwan
  • 3 School of Medicine, Wesley Hospital and Greenslopes Private Hospital, University of Queensland and Wesley Medical Centre, Brisbane, Australia
  • 4 Division of Cardiology, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea
  • 5 Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
  • 6 Department of Medicine, University of Queensland, Brisbane, Australia
  • 7 Cardiology Unit, Department of Medicine, Faculty of Medicine, Thammasat University, Pathumthani, Thailand
  • 8 Global Medical, Amgen Korea, Seoul, South Korea
  • 9 Global Medicine, Amgen Asia Holdings Ltd, Hong Kong, China
  • 10 Global Medical, Amgen Biopharmaceuticals Malaysia Sdn Bhd, Selangor, Malaysia
Cardiol Ther, 2024 Dec;13(4):737-760.
PMID: 39455535 DOI: 10.1007/s40119-024-00384-3

Abstract

INTRODUCTION: Real-world data are needed to understand the effectiveness of new therapeutic options for low-density lipoprotein cholesterol (LDL-C) reduction in Asia-Pacific clinical practice. Description of evolocumab use among adults with establisHed Atherosclerotic cardiovascuLar diseasE or hypercholesterolemia in ASia-Pacific region (HALES) was performed to better understand characteristics of and clinical decision-making for adults with established atherosclerotic cardiovascular disease/hypercholesterolemia after local evolocumab approval.

METHODS: The HALES observational study, conducted at 33 sites (Hong Kong, Thailand, South Korea, Singapore, Taiwan, and Australia) comprised (1) chart review of patients who received evolocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i), and (2) physician/patient survey and one-time data collection of patients with high cardiovascular risk initiating evolocumab or initiating/continuing non-PCSK9i lipid-lowering therapy. Patients could only enroll in (1) or (2).

RESULTS: Chart review included 724 very high-risk patients initiating evolocumab from regulatory approval to 2021. From median baseline LDL-C of 3.2 mmol/L (123.7 mg/dL), patients had a median percent change in LDL-C of - 60.8% at 1-6 months. Goal achievement increased from 7.9% to 69.8% for

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications